ABVC BioPharma, Inc. (ECOC) Net margin 2018–2025
ABVC BioPharma, Inc. (ECOC) net profit margin by fiscal year — reported net income divided by reported revenue.
-2671.8%FY2025 · since FY2018: -87184.2% → -2671.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -2671.8% | -1709.7 pp |
| FY2024 | -962.1% | +4147.1 pp |
| FY2023 | -5109.3% | -3415.8 pp |
| FY2022 | -1693.5% | +1915.0 pp |
| FY2021 | -3608.5% | -1415.4 pp |
| FY2020 | -2193.1% | -1632.6 pp |
| FY2019 | -560.5% | +86623.6 pp |
| FY2018 | -87184.2% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More ECOC financial trends
ECOC RevenueECOC Net incomeECOC Gross profitECOC Gross marginECOC Operating incomeECOC Operating marginECOC Operating cash flowECOC Free cash flowECOC Capital expendituresECOC Return on equityECOC Stock buybacksECOC Dividends paidECOC Total assetsECOC Total liabilitiesECOC Shareholders’ equityECOC overview →